Video

The Burden of Treatment Resistant Depression

Author(s):

Ryan J. Wakim, MD, DFAPA,Merrideth Leggat, MD

Ryan J. Wakim, MD, DFAPA, explores the causes and diagnostic criteria for treatment resistant depression. He also discusses the importance of comprehensive assessment and personalized approaches to care.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Related Content
Study Identifies Homelessness as a Predictor Against Clozapine Use
November 22nd 2024

Study Identifies Homelessness as a Predictor Against Clozapine Use

Chelsie Derman
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Kara Margolis, MD: Link Between Maternal SSRI Exposure, Increased Constipation Risk in Infants
November 13th 2024

Kara Margolis, MD: Link Between Maternal SSRI Exposure, Increased Constipation Risk in Infants

Chelsie Derman
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Hannibal Person, MD | Credit: X.com
November 9th 2024

Linaclotide Effective for Functional Constipation in Children with Neurodevelopmental Disorders

Patrick Campbell
Phase 3 Data Shows Lumateperone Delays Schizophrenia Relapse Longer Than Placebo
November 6th 2024

Phase 3 Data Shows Lumateperone Delays Schizophrenia Relapse Longer Than Placebo

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.